A message from Bora’s CEO Bobby ShengA letter to our partners, customers, and all stakeholders: As the world is fighting to contain the COVID-19 (the coronavirus), I wanted to reach out and provide an update on the actions that Bora is taking to prevent the spread of the virus, ensure business continuity, and support the health and well-being of our customers, employees and communities. The...
Skilled manufacturing staff to be retained as site becomes Bora Pharmaceuticals' flagship North American facilityBora Pharmaceuticals Co., Ltd (6472.TWO) and GSK announced today they have entered into an agreement under which Bora Pharmaceuticals will acquire GSK's Mississauga, Ontario (Canada) facility. The GSK facility produces approximately 50 different products for over 100 markets worldwide...
Bora, a contract development and manufacturing organization (CDMO) that specializes in complex modified release (MR) products and solvent production, has announced the opening of its first North American office in Delaware, U.S.The Asia-Pacific (APAC)-headquartered CDMO, which has invested over $60 million in acquiring world class facilities in recent years, has established the office as part of...
Pharmaceuticals are shifting towards developing modified release dosage formsIn line with this, the pharmaceutical industry is seeing a shift to develop modified release dosage forms that can deliver more therapeutic value and better outcomes for different groups, such as pediatric and geriatric patients. Bora's Business Development Department spoke to Pharmaceutical Technology Europe to discuss...